• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤患者中玛格罗利单抗联合用药的2期多臂研究最终结果
EJHaem. 2025 Jun 6;6(3):e70072. doi: 10.1002/jha2.70072. eCollection 2025 Jun.
2
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.贝兰他单抗莫福汀联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（DREAMM-7）：一项全球、随机、开放标签的3期试验的总生存更新分析
Lancet Oncol. 2025 Jul 15. doi: 10.1016/S1470-2045(25)00330-4.
3
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.使用治疗权重逆概率法比较西达基奥仑赛与传统治疗方案治疗来那度胺难治性多发性骨髓瘤患者的生存结局
Adv Ther. 2025 Jul 4. doi: 10.1007/s12325-025-03278-5.
4
Carfilzomib plus pomalidomide and dexamethasone as salvage therapy in patients with relapsed or refractory multiple myeloma in China: a retrospective study.卡非佐米联合泊马度胺及地塞米松在中国复发或难治性多发性骨髓瘤患者中的挽救治疗：一项回顾性研究
Transl Cancer Res. 2025 Jun 30;14(6):3351-3358. doi: 10.21037/tcr-2024-2688. Epub 2025 Jun 26.
5
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.卡非佐米-来那度胺-地塞米松对比来那度胺-地塞米松治疗不适合自体干细胞移植的新诊断骨髓瘤患者（EMN20）：一项随机、开放标签、多中心3期试验
Lancet Haematol. 2025 Aug;12(8):e621-e634. doi: 10.1016/S2352-3026(25)00162-0.
6
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.复发或难治性多发性骨髓瘤患者中，贝兰他单抗马福多汀、硼替佐米与地塞米松联合用药对比达雷妥尤单抗、硼替佐米与地塞米松联合用药的患者报告结局（DREAMM-7）：一项3期、开放标签、随机对照试验的结果
Lancet Haematol. 2025 Jul 15. doi: 10.1016/S2352-3026(25)00163-2.
7
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial.与接受卡非佐米、地塞米松和达雷妥尤单抗治疗的复发/难治性多发性骨髓瘤患者相比，接受卡非佐米和地塞米松治疗的患者的健康相关生活质量：3期CANDOR试验患者报告结局分析。
Clin Lymphoma Myeloma Leuk. 2025 Aug;25(8):590-605. doi: 10.1016/j.clml.2025.02.005. Epub 2025 Feb 19.
8
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.在英国，elranatamab与现实世界中针对三重暴露复发和难治性多发性骨髓瘤的治疗结果比较。
BMC Cancer. 2025 Jul 25;25(1):1219. doi: 10.1186/s12885-025-14624-9.
9
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.硼替佐米、美法仑和泼尼松诱导治疗后使用来那度胺和地塞米松，与卡非佐米、来那度胺和地塞米松联合或不联合达雷妥尤单抗用于老年、健康的新诊断多发性骨髓瘤患者（GEM-2017FIT）：一项3期、开放标签、多中心随机临床试验
Lancet Haematol. 2025 Aug;12(8):e588-e598. doi: 10.1016/S2352-3026(25)00143-7.
10
Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15).依鲁替尼联合来那度胺/地塞米松治疗复发/难治性多发性骨髓瘤（AFT-15）
Cancers (Basel). 2025 Jul 23;17(15):2433. doi: 10.3390/cancers17152433.

本文引用的文献

1
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis).LocoMMotion 研究：复发/难治性多发性骨髓瘤三药暴露患者的真实世界现行标准治疗 - 2 年随访（最终分析）。
Leukemia. 2024 Dec;38(12):2554-2560. doi: 10.1038/s41375-024-02404-6. Epub 2024 Sep 25.
2
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤治疗策略的最新进展
Cancers (Basel). 2024 Aug 23;16(17):2931. doi: 10.3390/cancers16172931.
3
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.未经治疗的 AML 患者中抗分化簇 47 抗体 Magrolimab 联合阿扎胞苷的耐受性和疗效：Ib 期结果。
J Clin Oncol. 2023 Nov 1;41(31):4893-4904. doi: 10.1200/JCO.22.02604. Epub 2023 Sep 13.
4
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.Magrolimab 联合阿扎胞苷治疗高危骨髓增生异常综合征患者的 Ib 期研究的最终结果。
J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8.
5
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.一项关于马吉妥昔单抗联合方案治疗复发/难治性多发性骨髓瘤的 II 期多臂研究。
Future Oncol. 2023 Jan;19(1):7-17. doi: 10.2217/fon-2022-0975. Epub 2023 Feb 13.
6
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.LocoMMotion 研究：一项针对复发和/或难治性多发性骨髓瘤患者的真实临床实践中现行标准治疗的前瞻性、非干预性、多国研究。
Leukemia. 2022 May;36(5):1371-1376. doi: 10.1038/s41375-022-01531-2. Epub 2022 Mar 24.
7
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.髓系恶性肿瘤中巨噬细胞免疫检查点CD47的治疗靶向作用
Front Oncol. 2020 Jan 22;9:1380. doi: 10.3389/fonc.2019.01380. eCollection 2019.
8
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.靶向CD47作为多发性骨髓瘤的新型免疫疗法
Cancers (Basel). 2020 Jan 28;12(2):305. doi: 10.3390/cancers12020305.
9
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.多发性骨髓瘤中对现行标准治疗产生耐药性的生物学背景。
Cells. 2019 Nov 13;8(11):1432. doi: 10.3390/cells8111432.
10
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.对 CD38 靶向单克隆抗体治疗耐药的多发性骨髓瘤患者的结局。
Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.

复发/难治性多发性骨髓瘤患者中玛格罗利单抗联合用药的2期多臂研究最终结果

Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.

作者信息

Paul Barry, Minarik Jiri, Cottini Francesca, Gasparetto Cristina, Khouri Jack, Gandhi Mitul, Hillengass Jens, Levy Moshe, Liedtke Michaela, Manda Sudhir, Sandhu Irwindeep, Sborov Douglas, Spicka Ivan, Usmani Saad, Dong Mei, Gu Lin, Leung Carmen, Doshi Parul, Chen Christine, Pour Ludek

机构信息

Atrium Health Levine Cancer Institute Wake Forest University School of Medicine Charlotte North Carolina USA.

Fakultni Nemocnice Olomouc Olomouc Czech Republic.

出版信息

EJHaem. 2025 Jun 6;6(3):e70072. doi: 10.1002/jha2.70072. eCollection 2025 Jun.

DOI:10.1002/jha2.70072
PMID:40485906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12143418/
Abstract

INTRODUCTION

Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy.

METHODS

This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR).

RESULTS

ORR was 14.3% (Magro+Dara; = 14), 20.0% (Magro+Pd; = 10) and 36.4% (Magro+Kd; = 11). There were two dose-limiting toxicities: febrile neutropenia (Magro+Dara) and infusion-related reaction (Magro+Pd). Grade ≥ 3 Magro-related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE-related; neither was Magro related.

CONCLUSION

As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited.

TRIAL REGISTRATION

This trial was registered at www.clinicaltrials.gov as #NCT04892446.

摘要

引言

先前接受过治疗的复发/难治性多发性骨髓瘤（RRMM）患者预后较差且治疗选择有限，这凸显了对具有持久疗效的安全治疗方法的需求。

方法

这项2期研究评估了马格罗利单抗（Magro）联合达雷妥尤单抗（Dara）或泊马度胺/地塞米松（Pd）或卡非佐米/地塞米松（Kd）用于RRMM的疗效。主要疗效终点为客观缓解率（ORR）。

结果

ORR分别为14.3%（Magro+Dara；n = 14）、20.